Chapter 4. Pulmonary Arterial Hypertension Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
4.4. Endothelin Receptor Antagonists (ERAs)
4.4.1. Endothelin Receptor Antagonists (ERAs) Market, 2021-2033 (USD Million)
4.5. PDE-5 Inhibitors
4.5.1. PDE-5 Inhibitors Market, 2021-2033 (USD Million)
4.6. Prostacyclin and Prostacyclin Analogs
4.6.1. Prostacyclin and Prostacyclin Analogs Market, 2021-2033 (USD Million)
4.7. SGC Stimulators
4.7.1. SGC Stimulators Market, 2021-2033 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Regulatory Framework
7.2.4.4. Mexico Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3. Europe
7.3.1. Europe Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Regulatory Framework
7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Regulatory Framework
7.3.4.4. France Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.7. Sweden
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Regulatory Framework
7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.8. Norway
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Regulatory Framework
7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.3.9. Denmark
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Regulatory Framework
7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4. Asia-Pacific
7.4.1. Asia-Pacific Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. China Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. India Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.5. Latin America
7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. ArgentinaPulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.5.4. Rest of LATAM
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Rest of LATAM Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.6. MEA
7.6.1. MEA Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2021-2033 (USD Million)
List of Tables
Table 1 List of secondary sources
Table 2 Average selling prices for approved PAH agents in the U.S. (2023)
Table 3 Summary of pipeline analysis for Early Phase I & Phase I PAH agents
Table 4 Summary of pipeline analysis for Phase II PAH agents
Table 5 Summary of pipeline analysis for Phase III PAH agents
Table 6 Summary of pipeline analysis for Phase IV PAH agents
Table 7 Summary of pipeline analysis for Phase IV PAH agents
Table 8 Global Pulmonary Arterial Hypertension (PAH) market, by Region, 2021-2033 ( USD Million)
Table 9 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 10 Global Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 11 Global Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 12 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 13 North America Pulmonary Arterial Hypertension market, by Country, 2021-2033 (USD Million)
Table 14 North America Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 15 North America Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 16 North America Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 17 U.S. Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 18 U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 19 U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 20 Canada Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 21 Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 22 Canada Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 23 Europe Pulmonary Arterial Hypertension market, by country, 2021-2033 (USD Million)
Table 24 Europe Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 25 Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 26 Europe Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 27 UK Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 28 UK Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 29 UK Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 30 Germany Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 31 Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 32 Germany Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 33 France Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 34 France Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 35 France Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 36 Italy Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 37 Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 38 Italy Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 39 Spain Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 40 Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 41 Spain Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 42 Sweden Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 43 Sweden Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 44 Sweden Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 45 Denmark Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 46 Denmark Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 47 Denmark Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 48 Norway Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 49 Norway Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 50 Norway Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 51 Asia-Pacific Pulmonary Arterial Hypertension market, by country, 2021-2033 (USD Million)
Table 52 Asia-Pacific Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 53 Asia-Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 54 Asia-Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 55 China Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 56 China Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 57 China Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 58 Japan Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 59 Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 60 Japan Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 61 India Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 62 India Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 63 India Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 64 Australia Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 65 Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 66 Australia Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 67 South Korea Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 68 South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 69 South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 70 Thailand Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 71 Thailand Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 72 Thailand Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 73 Latin America Pulmonary Arterial Hypertension market, by country, 2021-2033 (USD Million)
Table 74 Latin America Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 75 Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 76 Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 77 Brazil Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 78 Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 79 Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 80 Mexico Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 81 Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 82 Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 83 Argentina Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 84 Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 85 Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 86 MEA Pulmonary Arterial Hypertension market, by Country, 2021-2033 (USD Million)
Table 87 MEA Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 88 MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 89 MEA Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 90 South Africa Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 91 South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 92 South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 93 Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 94 Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 95 Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 96 UAE Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 97 UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 98 UAE Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
Table 99 Kuwait Pulmonary Arterial Hypertension market, by Type, 2021-2033 (USD Million)
Table 100 Kuwait Pulmonary Arterial Hypertension market, by Route of Administration, 2021-2033 (USD Million)
Table 101 Kuwait Pulmonary Arterial Hypertension market, by Drug Class, 2021-2033 (USD Million)
List of Figures
Figure 1 Pulmonary Arterial Hypertension market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and application outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Pulmonary Arterial Hypertension market dynamics
Figure 12 Pulmonary Arterial Hypertension market Porter’s five forces analysis
Figure 13 Pulmonary Arterial Hypertension market PESTLE analysis
Figure 14 Drug Class market, 2021-2033 (USD Million)
Figure 15 Endothelin Receptor Antagonists (ERAs) market, 2021-2033 (USD Million)
Figure 16 PDE-5 Inhibitors market, 2021-2033 (USD Million)
Figure 17 Prostacyclin and Prostacyclin Analogs market, 2021-2033 (USD Million)
Figure 18 SGC Stimulators market, 2021-2033 (USD Million)
Figure 19 Type market, 2021-2033 (USD Million)
Figure 20 Branded market, 2021-2033 (USD Million)
Figure 21 Generics market, 2021-2033 (USD Million)
Figure 22 Route of Administration market, 2021-2033 (USD Million)
Figure 23 Oral market, 2021-2033 (USD Million)
Figure 24 Intravenous/ Subcutaneous market, 2021-2033 (USD Million)
Figure 25 Inhalational market, 2021-2033 (USD Million)
Figure 26 Pulmonary Arterial Hypertension market revenue, by region
Figure 27 Regional marketplace Key takeaways
Figure 28 North America pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 29 U.S. country dynamics
Figure 30 U.S. pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 31 Canada country dynamics
Figure 32 Canada pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 33 Mexico country dynamics
Figure 34 Mexico pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 35 Europe pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 36 UK country dynamics
Figure 37 UK pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 38 Germany country dynamics
Figure 39 Germany pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 40 France country dynamics
Figure 41 France pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 42 Italy country dynamics
Figure 43 Italy pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 44 Spain country dynamics
Figure 45 Spain pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 46 Norway country dynamics
Figure 47 Norway pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 48 Sweden country dynamics
Figure 49 Sweden pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 50 Denmark country dynamics
Figure 51 Denmark pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 52 Asia-Pacific pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 53 Japan country dynamics
Figure 54 Japan pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 55 China country dynamics
Figure 56 China pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 57 India country dynamics
Figure 58 India pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 59 Australia country dynamics
Figure 60 Australia pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 61 South Korea country dynamics
Figure 62 South Korea pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 63 Thailand country dynamics
Figure 64 Thailand pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 65 Latin America pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 66 Brazil country dynamics
Figure 67 Brazil pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 68 Argentina country dynamics
Figure 69 Argentina pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 70 MEA pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 71 South Africa country dynamics
Figure 72 South Africa pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 73 Saudi Arabia country dynamics
Figure 74 Saudi Arabia pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 75 UAE country dynamics
Figure 76 UAE pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 77 Kuwait country dynamics
Figure 78 Kuwait pulmonary arterial hypertension market, 2021-2033 (USD Million)
Figure 79 Company categorization
Figure 80 Company market position analysis
Figure 81 Strategic framework
